Moving New Diagnostics into the Clinic in the 21st Century

Calum MacRae, MD
Lead, One Brave Idea

Introduction and Overview by Dr. Calum MacRae

Paul Ridker, MD
Director of the Center for Cardiovascular Disease Prevention and the Eugene Braunwald Professor of Medicine, Brigham and Women’s Hospital

The Challenges of Implementation: What we learned with hsCRP by Dr. Paul Ridker

Marc S. Penn, MD
Co-Founder and Chief Medical Officer, Cleveland HeartLab, Quest Diagnostics

Inflammatory Markers for Defining Cardiovascular risk by Dr. Marc Penn

Rahul Deo, MD
Chief Data Scientist, One Brave Idea

Novel Approaches to Diagnostic Biomarkers by Dr. Rahul Deo

Naeem Khan, MD
Vice President US Medical Affairs, Cardiovascular and Metabolic Diseases, AstraZeneca

Why we are involved in One Brave Idea by Dr. Naeem Khan

Panel discussion


  • Date: Monday, December 09, 2019
  • Category: Videos
  • Description: Together with One Brave Idea™ we’ll explore the reasons traditional biomarkers for coronary heart disease (CHD) are insufficient, and why we must work across boundaries, old assumptions, and disciplines to reimagine the future in order to prevent, detect, and treat CHD.
    Hosted by: One Brave Idea™ and Quest Diagnostics®